Skip to main content
. 2017 Feb 22;2017:3414910. doi: 10.1155/2017/3414910

Figure 1.

Figure 1

Contribution of AdnaTest markers to circulating tumour cell (CTC) positivity. The contribution of EPCAM, MUC1, ERBB2 and of all their combinations to CTC positivity is reported for M0 and M+ cases at each time point analyzed (baseline, T0; after first, T1; and second, T2, cycle of therapy). Numbers within the bars refer to the number of CTC-positive samples expressing specific markers or their combinations as indicated by the colour code.